Program
Riluzole
Also written as “Riluzole tablet”, “Intrathecal Riluzole” and “Riluzole 50 mg orodispersible film”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Neuralgia, Postherpetic · Huntington Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 20 open or running | phase 4since Oct 10, 2007 | Jan 13, 2006 | none ahead |
| Biohaven Pharmaceuticals | 10 open or running | phase 1since Apr 17, 2018 | Apr 17, 2018 | none ahead |
| Brain Trust Bio | 11 open or running | phase 1since May 8, 2024 | May 8, 2024 | none ahead |
| Cross Research | 10 open or running | phase 1since Mar 8, 2021 | Mar 8, 2021 | none ahead |
Also a collaborator on its studies: Zambon SpA and cognitive-research-corporation.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2006First study: phase 3 study in Huntington DiseaseNew to SanofiSanofi · NCT00277602 · 537 enrolled
- Oct 10, 2007Phase 4 study in Amyotrophic Lateral SclerosisSanofi · NCT00542412 · 414 enrolled · Canada
- Apr 17, 2018Biohaven Pharmaceuticals's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to Biohaven PharmaceuticalsBiohaven Pharmaceuticals · NCT03520517 · 22 enrolled · United States
- Mar 8, 2021Cross Research's first study: phase 1 study in Healthy ParticipantsNew to Cross ResearchCross Research · NCT04819438 · 54 enrolled · Switzerland
- May 8, 2024Brain Trust Bio's first study: phase 1 study in Amyotrophic Lateral SclerosisNew to Brain Trust BioBrain Trust Bio · NCT07093268 · 10 planned · Australia
TargetBeta
“Sodium channel alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same 10 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07093268Amyotrophic Lateral Sclerosis · Australia | 1 | Not yet recruiting | Brain Trust Bio | Jun 15, 2026 | 10 |
| NCT04819438Healthy Participants · Switzerland | 1 | Completed | Cross Research | Mar 14, 2021 | 54 |
| NCT03520517Amyotrophic Lateral Sclerosis · United States | 1 | Completed | Biohaven Pharmaceuticals | Oct 8, 2018 | 22 |
| NCT00542412Amyotrophic Lateral Sclerosis · Canada | 4 | Completed | Sanofi | 414 | |
| NCT00277602Huntington Disease | 3 | Completed | Sanofi | Jul 2004 | 537 |
How it is read
Names in the registry
- “Riluzole”, 2 entries
- “Riluzole tablet”, 1 entry
- “Intrathecal Riluzole”, 1 entry
- “Riluzole 50 mg orodispersible film”, 1 entry
- “BHV-0223”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 3 studies
- Neuralgia, Postherpetic, 1 study
- Huntington Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.